U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

The leaked budget draft, if approved by Congress, would reduce the FDA’s budget authority, indicating more disruption could ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...